Bristol Myers Squibb posted higher first-quarter revenue boosted by its portfolio of newer treatments for heart and blood conditions.
About the Author
Discover more from InfoVera USA
Subscribe to get the latest posts sent to your email.
US News, Trends & Trusted Information
